EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[´Ù¾çÇÑ ´ëÀå Áúȯ 011 - ¼Ò¾Æ Å©·Ðº´] - ðû

Previous | Next

»ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â°ú ÃÖ¿¬È£ ±³¼ö´Ô ±â»ç¸¦ ¼Ò°³ÇÕ´Ï´Ù (2015-12-3. °æÇâ½Å¹®).

Äڷк´ ȯÀÚ°¡ ±¹³»¿¡¼­ ²ÙÁØÈ÷ ´Ã°í ÀÖ´Ù. °Ç°­º¸Çè½É»çÆò°¡¿ø ÀڷḦ º¸¸é 2014³â Å©·Ðº´ Áø·á ȯÀÚ´Â 1¸¸7284¸íÀ¸·Î, 2009³â¿¡ ºñÇØ 5³â ¸¸¿¡ 41.3% Áõ°¡Çß´Ù. Å©·Ðº´Àº ¼ºÀå±âÀÎ ¼Ò¾Æû¼Ò³â ȯÀÚ ºñÁßÀÌ Å©´Ù´Â Á¡¿¡¼­ ¾î¸° ½Ã±â¿¡ º¸´Ù Àû±ØÀûÀÎ Ä¡·á ´ëÃ¥ÀÌ ¿ä±¸µÈ´Ù.

º¸°Çº¹ÁöºÎ´Â ¸¸ 0~18¼¼ÀÇ Å©·Ðº´ ȯÀÚ¿¡°Ô ±ÕÇü¿µ¾ç½Ä ¡®¿¤¸®¸àÅ»028¿¢½ºÆ®¶ó¡¯(1~18¼¼)¿Í ¾Æ¹Ì³ë»ê ºÐÀ¯ ¡®³×¿ÀÄÉÀÌÆ®¡¯(0~1¼¼) µî Ư¼ö¿µ¾ç½ÄÀ» Áö¿øÇÏ°í ÀÖ´Ù. Ư¼ö¿µ¾ç½Ä ½ÅûÀº ¸Å¿ù 1~5ÀÏ Áö¿ª º¸°Ç¼Ò¿¡ Áö¿ø½Åû¼­¿Í ±¸ºñ¼­·ù¸¦ Á¦ÃâÇÏ¸é µÈ´Ù.

»ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â°ú ÃÖ¿¬È£ ±³¼ö´Â ¡°¼Ò¾Æ Å©·Ðº´Àº Á¶±â¿¡ ÁýÁßÀûÀÎ Ä¡·á¸¦ ÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù¡±°í °­Á¶Çß´Ù. ¡®¼Ò¾Æû¼Ò³â Å©·Ðº´ ¹× ±Ë¾ç¼º´ëÀå¿° Ŭ¸®´Ð¡¯À» ¿î¿µÇϸ鼭 Ä¡·áÀÇ ÀûÀý¼º ¿¬±¸¿Í Ä¡·á ¾à¹°ÀÇ ¸ð´ÏÅ͸µ µîÀ» ÁÖµµÇÏ°í ÀÖ´Â ÃÖ ±³¼ö·ÎºÎÅÍ ¼Ò¾Æû¼Ò³â±â Å©·Ðº´ÀÇ È¿°úÀûÀÎ Ä¡·á¿Í °ü¸®¿¡ ´ëÇØ ¾Ë¾Æº»´Ù.

- Å©·Ðº´ Áõ»óÀº ¹«¾ùÀΰ¡¿ä.

¡°ÇѵΠ´Þ ÀÌ»óÀÇ ¸¸¼º¼³»ç¿Í º¹Åë ȤÀº Ç÷º¯, üÁß°¨¼Ò, Ç×¹®º´º¯(´©°ø¡¤Ä¡¿­¡¤Ä¡Áú µî) 3°¡Áö°¡ ÀÖÀ¸¸é Å©·Ðº´ÀÏ °¡´É¼ºÀÌ ¸Å¿ì Å®´Ï´Ù. ¹«¾ùº¸´Ù üÁß°¨¼Ò°¡ Ư¡ÀûÀÔ´Ï´Ù. 3~6°³¿ù¿¡ 5~10§¸À̳ª ºüÁö´Â ȯÀڵ鵵 ÀÖ½À´Ï´Ù. ¼Ò¾Æ ȯÀÚµéÀº ´ë°³ ¿µ¾çºÎÁ· »óÅ¿¡¼­ º´¿ø¿¡ ¿É´Ï´Ù. ´Ã º¹ÅëÀ̳ª ¼³»ç¿¡ ½Ã´Þ¸®ÁÒ. ÀÌ·± ¾ÆÀ̵éÀº ¼Ò¾Æ¼ÒÈ­±â Àü¹®ÀÇ°¡ ÀÖ´Â ÀÇ·á±â°üÀ¸·Î »¡¸® °¡¼­ Áø·á¸¦ ¹Þ¾Æ¾ß ÇÕ´Ï´Ù.¡±

ÃÖ¿¬È£ ±³¼ö´ÔÀº ¼Ò¾Æ Å©·Ðº´ ȯÀÚ ÄÚȣƮ¸¦ ±¸¼ºÇÏ¿© È¿°úÀûÀÎ Ä¡·á¹ý °³¹ß¿¡ ¿­½ÉÀ̽ʴϴÙ. ³í¹® Çϳª¸¦ ¼Ò°³ÇÕ´Ï´Ù. ¼Ò¾Æ¿¡¼­ infliximabÀ» Ãʱ⿡ »ç¿ëÇÏ´Â °ÍÀÌ ÁÁ´Ù°í ÇÕ´Ï´Ù.

Infliximab "Top-Down" Strategy is Superior to "Step-Up" in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease. J Pediatr Gastroenterol Nutr. 2015

METHODS: A total of 31 patients (group A) were treated with early infliximab induction ("top-down" strategy) and 20 patients (group B) refractory to conventional therapy underwent infliximab treatment ("step-up" strategy).

RESULTS: The relapse-free rates at 3 years were 35.5% in group A and 15.0% in group B. Overall remission period rate for 3 years also showed a significant difference between the 2 groups (92.1% ¡¾ 7.2% vs 78.3% ¡¾ 16.6%; P = 0.005). Multivariable analysis revealed that the duration from the initial diagnosis to infliximab infusion was the only factor associated with relapse-free remission for 3 years.

CONCLUSIONS: Earlier introduction of infliximab is recommended in pediatric patients with moderate to severe Crohn disease.

2022³â 12¿ù ±è¹ÌÁø ±³¼ö´ÔÀÇ °­ÀǸ¦ µé¾ú½À´Ï´Ù.

PDF

[2015] Á¦°¡ Å©·Ðº´À» Áø·áÇÏÁö ¾Ê°í À־ ¼ºÀΰú ºñ±³´Â ¾î·Á¿ü½À´Ï´Ù. ¸î ºÐ²² ÀÚ¹®À» ±¸ÇØ º¸¾Ò½À´Ï´Ù.


[2015-12-5. Àü¹®°¡ ÃÌÆò 1]

Àúµµ Àü¹®¼ºÀÌ ¾ø¾î¼­ comment¸¦ Çϱâ´Â ¾î·Æ½À´Ï´Ù. ±¹³»ÀÇ °æ¿ì ¼Ò¾Æ Å©·Ðº´ ȯÀڴ ƯȭµÈ ¼Ò¾Æ°ú¿¡¼­ Áø·á¸¦ ÁÖ·Î ´ã´çÇÏ°í À־ ³»°ú¿¡¼­ Áø·áÇÏ´Â °æ¿ì´Â º°·Î ¾ø´Â °ÍÀ¸·Î ¾Ë°í ÀÖ½À´Ï´Ù. ±â»ç¿Í ³í¹®ÀÇ ³»¿ë¿¡ ´ëÇؼ­´Â ´ëºÎºÐ µ¿ÀÇÇÕ´Ï´Ù. ¼Ò¾ÆÀÇ °æ¿ì ¼ºÀκ¸´Ù ¿¹ÈÄ°¡ ÁÁÁö ¾Ê°í, ÀÌȯ ±â°£ÀÌ ±æ¾î¼­ ºñ°¡¿ªÀû Àå±â ¼Õ»óÀÌ ÃÊ·¡µÉ °¡´É¼ºÀÌ ¸¹±â ¶§¹®¿¡ Á¶±â¿¡ »ý¹°ÇÐÀû Á¦À縦 Åõ¿©ÇÒ ÇÊ¿ä°¡ ÀÖ½À´Ï´Ù.

Àß ¾Æ½Ã°ÚÁö¸¸ ·ù¸¶Æ¼½º °üÀý¿°À̵ç Å©·Ðº´°ú °°Àº ¿°Áõ¼ºÀåÁúȯÀ̵ç Áúº´ÀÇ Ãʱ⠴ܰ迡¼­´Â ¿°ÁõÀÌ ÁÖµÈ º´ÅÂÁö¸¸, ½Ã°£ÀÌ Áö³¯¼ö·Ï ¼¶À¯È­³ª ÇùÂøÀÇ ÇüÅ·Πº¯ÇüµÇ°Ô µË´Ï´Ù. ¿°ÁõÀº »ý¹°ÇÐÀû Á¦Á¦¸¦ Æ÷ÇÔÇÑ Ç׿°ÁõÄ¡·á¿¡ ÀÇÇØ Á¶ÀýµÇ°í °¡¿ªÀûÀ¸·Î ÁÁ¾ÆÁú ¼ö ÀÖÁö¸¸, ¼¶À¯È­³ª ÇùÂøÀÇ ÇüÅ´ »ý¹°ÇÐÀû Á¦Á¦¸¦ Æ÷ÇÔÇÑ ¾î¶² Ç׿°ÁõÄ¡·á¸¦ ÇÏ´õ¶óµµ °¡¿ªÀûÀ¸·Î ÁÁ¾ÆÁöÁö ¾Ê°í ¼ö¼úÀ» ÅëÇؼ­¸¸ ÇØ°áÇÒ ¼ö Àֱ⠶§¹®¿¡, ¿°ÁõÀÌ ÁÖµÈ º´ÅÂÀÎ Ãʱ⿡ ¿°Áõ Ä¡·á¸¦ °­·ÂÇÏ°Ô ÇÏ´Â top-down Ä¡·á°¡ ´Ü°èÀûÀ¸·Î Ä¡·á¸¦ ÁøÇàÇÏ´Â step-up Ä¡·áº¸´Ù ¼³µæ·ÂÀÌ ÀÖ½À´Ï´Ù.

´Ù¸¸, °úÀ×Ä¡·á³ª º¸Çè±Þ¿© µîÀÇ ¹®Á¦·Î ÀÎÇØ ¾ÆÁ÷±îÁö´Â top-down Ä¡·á¸¦ º¸ÆíÀûÀ¸·Î ¹Þ¾ÆµéÀ̱⠾î·Á¿î °ÍÀÌ ±¹³» Çö½ÇÀÔ´Ï´Ù. ¶ÇÇÑ, ¼Ò¾ÆÀÇ °æ¿ì¿¡´Â ¼ºÀΰú ´Ù¸£°Ô ¾à¹° Ä¡·á ¿Ü¿¡ ¿µ¾ç Ä¡·á°¡ ÁÖ¿äÇÑ Ä¡·áÁßÀÇ Çϳª¶ó°í ¾Ë°í ÀÖ½À´Ï´Ù.


[2015-12-5. Àü¹®°¡ ÃÌÆò 2]

°³ÀÎÀûÀ¸·Î ¼Ò¾ÆÅ©·Ð ȯÀÚ´Â °ÅÀÇ ¾ø´Ù½ÃÇÇ Çϱ⿡ Ä¿¸àÆ®¶ó°í ÇÒ ¼öÁØÀº ¸øµÇ¸ç ¸Å¿ì Á¶½É½º·´½À´Ï´Ù.

Å©·Ðº´Àº ÀϹÝÀûÀ¸·Î ¹ßº´¿¬·ÉÀÌ ³·À» ¼ö·Ï ¿¹ÈÄ°¡ ÁÁÁö ¾Ê±â ¶§¹®¿¡ ¼Ò¾ÆÅ©·ÐÀÇ °æ¿ì ¼ºÀκ¸´Ù ´õ ½ÉÇÑ °æ°ú¸¦ ¹âÀ» °¡´É¼ºÀÌ ³ô½À´Ï´Ù. °¡Á··ÂÀÌ ¼ºÀÎÅ©·Ðº´º¸´Ù ´õ ³ôÀ¸¸ç °ñ¹Ðµµ°¨¼Ò, ¼ºÀåÀå¾Ö, ½É¸®Àû ¹®Á¦ µîÀ» °ÞÀ» °¡´É¼ºÀÌ ¸¹½À´Ï´Ù. ÀÌȯ¹üÀ§ ¿ª½Ã ±¤¹üÀ§ÇÑ °æ¿ì°¡ ´õ ¸¹´Ù°í ÇÕ´Ï´Ù. ÀÌȯ±â°£¿¡ µû¸¥ ¼ö¼ú°¡´É¼ºÀº ¼ºÀΰú ºñ½ÁÇÑ Á¤µµ¶ó°í ÇÏÁö¸¸ ¹ßº´¿¬·ÉÀÌ ºü¸£¹Ç·Î ¼ö¼úÀ» ¹ÞÀ» °¡´É¼ºµµ ´ç¿¬È÷ ´õ ³ô´Ù°í ÇÒ ¼ö ÀÖ°Ú½À´Ï´Ù.

Å©·Ðº´ Ä¡·á¿¡´Â 5-ASAºÎÅÍ ÇѴܰ辿 ¿Ã¸®´Â ÀüÅëÀûÀÎ step up therapy¿Í ¹ßº´ÃʱâºÎÅÍ biologics¸¦ Àû±ØÀûÀ¸·Î »ç¿ëÇØ¾ß ÇÑ´Ù´Â top down therapy°¡ ÀÖ½À´Ï´Ù. µÎ ¹æ¹ý ´Ù Àå´ÜÁ¡ÀÌ Àֱ⠸¶·ÃÀε¥ ±¹³»¿¡¼­´Â ¼ºÀÎÀÇ °æ¿ì ´ëºÎºÐÀÇ ¼±»ý´ÔµéÀÌ accelerated step up ¹æ¹ýÀ» °¡Àå ¸¹ÀÌ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù (top downÀº ¾îÂ÷ÇÇ º¸Çè±Þ¿© ¹®Á¦·Î »ç¿ëÀÌ ¾î·Æ±âµµ ÇÕ´Ï´Ù).

¼±»ý´ÔÀÌ º¸¿©ÁֽŠ³í¹®Àº ¼Ò¾ÆÅ©·ÐÀÇ °æ¿ì top downÀÌ step upº¸´Ù ¿À·§µ¿¾È °üÇظ¦ À¯ÁöÇÒ ¼ö ÀÖÀ½À» º¸¿©ÁÖ°í ÀÖÀ¸¸ç Áß¿äÇÑ °á°ú¶ó°í »ý°¢ÇÕ´Ï´Ù. ´Ù¸¸ top downÀ» ÇßÀ½¿¡µµ ºÒ±¸ÇÏ°í ÀÌȯ±â°£ÀÌ 3³âÀÌ ³ÑÀº ȯ¾ÆµéÀÇ °æ¿ì Àý¹Ý ÀÌÇϸ¸ °üÇØ»óÅ¿¡ ÀÖ´Â °É º¸¸é ¾ÆÁ÷µµ Å©·Ðº´ Ä¡·á°¡ ½±Áö ¾ÊÀ½À» ÁüÀÛÇÒ ¼ö ÀÖÀ» µí ÇÕ´Ï´Ù.


[2015-12-5. Àü¹®°¡ ÃÌÆò 3]

¼Ò¾Æ ȯÀÚµéÀÌ ¼Ò¾Æ°ú¿¡ ´õ ¸¹ÀÌ °¡°ÚÁö¸¸ ¼ÒÈ­±â³»°ú¿¡¼­µµ ÀϺΠº¸±â´Â ÇÕ´Ï´Ù¸¸ ÃÖ¿¬È£ ¼±»ý´Ô ³í¹®¿¡ ´ëÇØ ÆòÇÏ´Â °ÍÀÌ ½±Áö´Â ¾Ê½À´Ï´Ù. ¸ÕÀú ¼Ò¾Æ Å©·Ðº´Àº ¼ºÀκ¸´Ù º´ÀÇ °æ°ú°¡ Á¶±Ý ´õ ³ª»Ú°í Á¶±â ¸é¿ªÁ¶ÀýÁ¦ Ä¡·á¿¡ ´ëÇØ ÀÌ¹Ì ±àÁ¤ÀûÀÎ °á°ú°¡ ÀÖ½À´Ï´Ù. ¼ºÀÎÀº ¾ÆÁ÷ Á¶±â ¸é¿ªÁ¶ÀýÁ¦ »ç¿ë¿¡ ´ëÇØ ³í¶õÀÌ ¸¹ÀÌ ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ »ý¹°ÇÐÀû Á¦Á¦¸¦ Ãʱ⿡ ¼Ò¾Æ³ª ¼ºÀο¡¼­ ½á¾ß ÇÏ´ÂÁö¿¡ ´ëÇؼ­´Â ¾ÆÁ÷ °³ÀÎÀûÀ¸·Î ºÎÁ¤ÀûÀÔ´Ï´Ù. ¾ÆÁÖ À§ÇèÀÎÀÚ°¡ ¸¹Àº °æ¿ì ÃÊÄ¡·á¿¡ µèÁö ¾ÊÀ» ¶§ »¡¸® ¾²´Â À̸¥¹Ù °íÀ§Ç豺¿¡¼­¸¸ ÀϺΠtop downÀ» ÇÏ´Â °ÍÀÌ ÁÁÁö ¾ÊÀ»±î »ý°¢ÇÕ´Ï´Ù. ¼ºÀο¡¼­ÀÇ ¿¬±¸µµ óÀ½¿¡´Â ´ç¿¬È÷ top down¿¡¼­ È¿°ú°¡ ÁÁÁö¸¸ ½Ã°£ÀÌ Áö³¯¼ö·Ï ±× Â÷ÀÌ°¡ Á¼ÇôÁ®¼­ °á±¹ Ãʱ⠻ç¿ë È¿°ú°¡ ¶³¾îÁö°Ô µÇ°í ´Ü¼øÈ÷ ¾Æ·¡ ³í¹®¿¡¼­Ã³·³ Áõ»ó Àç¹ß·ü·Î outcomeÀ» Æò°¡Çϱ⿡´Â ÇÑ°è°¡ ÀÖ½À´Ï´Ù. ´õ Àå±â ÃßÀûÇؼ­ ÀåÀýÁ¦¼ú °°Àº ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ´À³Ä°¡ °ü°ÇÀÌ°Ú½À´Ï´Ù.


[2015-12-8. Àü¹®°¡ ÃÌÆò 4]

¿ì¸® º´¿øÀ» ã´Â ¼Ò¾Æ Å©·Ðº´ ȯÀÚ¸¦ ¾à 5¸í Áø·áÇÑ °æÇèÀÌ ÀÖ½À´Ï´Ù. °¡Àå ¾î¸° ÇлýÀº ÃʵîÇб³ 5Çгâ, ±×¸®°í ÁßÇлýµé 4¸íÀ̾ú½À´Ï´Ù. ¸ðµÎ üÁß °¨¼Ò°¡ 10 kg Á¤µµ·Î ½ÉÇß½À´Ï´Ù. 5¸í Áß 3¸íÀÌ Ä¡·ç¸¦ µ¿¹ÝÇÏ°í ÀÖ¾ú½À´Ï´Ù. °¡Àå ¾î¸° ÃʵîÇлý ³²ÀÚ´Â Á¦°¡ Áö±Ý±îÁö Áø·áÇÑ Å©·Ðº´ ȯÀÚ Áß °¡Àå ½ÉÇÏ¿´½À´Ï´Ù. ´ëÀå ¿°ÁõÀÌ ³Ê¹« ½ÉÇؼ­ °Ë»çÇϸ鼭 ÇѼû¸¸ ½¬¾ú½À´Ï´Ù. 5¸í Áß 4¸í¿¡¼­ °üÀýÅëÀ» µ¿¹ÝÇÏ°í ÀÖ´Â µî Áõ»óÀÌ ½ÉÇß½À´Ï´Ù.

¾Æ½Ã´Ù½ÃÇÇ ¾î¸° ³ªÀÌ Å©·Ðº´È¯ÀÚµéÀº ¼ºÀå Àå¾Ö°¡ ¿Ã ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ºÅ×·ÎÀÌµå ¿ä±¸·®µµ ´õ ¸¹´Ù°í ÇÕ´Ï´Ù. 5¸í Áß 4¸íÀÌ »ý¹°ÇÐÀû Á¦Á¦¸¦ »ç¿ë ÁßÀε¥, ÁßÇлý 1¸íÀº ½ºÅ×·ÎÀÌµå »ç¿ë ÈÄ Áõ»óÀÌ È£ÀüµÇ¾î ¸é¿ª¾ïÁ¦Á¦¸¸ »ç¿ëÇÏ°í ÀÖ½À´Ï´Ù.

À¯·´ °¡À̵å¶óÀεµ ¼Ò¾Æ Å©·Ðº´Àº °ð¹Ù·Î »ý¹°ÇÐÀû Á¦Á¦¸¦ »ç¿ëÇ϶ó°í µÇ¾î Àִµ¥, ¾Æ½±°Ôµµ ¿ì¸®³ª¶ó´Â ¾ÆÁ÷µµ ½ºÅ×·ÎÀ̵å, ¸é¿ª¾ïÁ¦Á¦¸¦ »ç¿ëÇÑ ÈÄ¿¡¾ß »ý¹°ÇÐÀû Á¦Á¦ »ç¿ëÀÌ °¡´ÉÇÕ´Ï´Ù. ¼Ò¾Æ¼ÒÈ­±âÇÐȸ¿¡¼­ ¾Ö½á¼­ º¸ÇèÀ» º¯°æ½ÃÄÑ¾ß ÇÒÅÙµ¥¿ä...

Àú´Â °¡´ÉÇÏ¸é º¸Çè¿¡ ¾î±ß³ªÁö ¾Êµµ·Ï »ý¹°ÇÐÀû Á¦Á¦¸¦ »¡¸® »ç¿ëÇß½À´Ï´Ù. ¿øÄ¢ÀûÀ¸·Î thiopurine Á¦Á¦´Â ¾à 3°³¿ù Á¤µµ »ç¿ëÇØ¾ß È¿°ú°¡ ÀÖÁö¸¸, ±×·¸°Ô ±â´Ù¸®±â°¡ ½±Áö ¾Ê½À´Ï´Ù. ½ÇÁ¦·Î ½ºÅ×·ÎÀ̵带 °¨·®Çϸ鼭 ´Ù½Ã ¼³»ç, °üÀýÅë, º¹ÅëÀ» È£¼ÒÇÏ¿© ºÎµæÀÌ 2ÁÖ Á¤µµ ÀÖ´Ù°¡ °ð¹Ù·Î ·¹¹ÌÄÉÀ̵带 Åõ¿©ÇÏ¿´½À´Ï´Ù. È޹̶ó´Â ¿ÃÇØ 5¿ùºÎÅÍ ¼Ò¾ÆÅ©·Ðº´¿¡ º¸Çè ±Þ¿©°¡ ÀÎÁ¤µÇ°í ÀÖ½À´Ï´Ù.

IC valve

½Äµµ

ÀÌ »çÁøÀÇ ÁÖÀΰøÀº thiopurine Á¦Á¦ 25 mgÀ» ¾à 3ÁÖ »ç¿ëÇϸ鼭 ¹éÇ÷±¸°¡ 100À¸·Î °¨¼ÒÇؼ­ °ÅÀÇ ÇÑ ´Þ µ¿¾È È¥³µ½À´Ï´Ù. ¾Æ»êº´¿ø ¾ç¼®±Õ ¼±»ý´Ô²²¼­ Nature Genetics¿¡ ¹ßÇ¥ÇÑ ¹Ù¿Í °°Àº À¯ÀüÇü ¾Æ´Ñ°¡ »ý°¢ÇÕ´Ï´Ù (Yang SK. Nat Genet 2014). ·¹¹ÌÄÉÀ̵带 »ç¿ëÇϸ鼭 Áõ»óÀÌ È£ÀüµÇ¾úÀ¸³ª, ÀÌÂ÷Àû ¹ÝÀÀ ¼Ò½ÇÀÌ ¹ß»ýÇÏ¿© °í»ýÇÏ´ø Áß ÈÞ¹Ì¶ó°¡ º¸ÇèÀÌ µÇ¾î ÇöÀç´Â ºñ±³Àû °üÇØ »óŸ¦ À¯ÁöÇÏ°í ÀÖ½À´Ï´Ù. Å« º´¿ø °¡¶ó°í Çصµ ±»ÀÌ Àú¿¡°Ô ¿É´Ï´Ù. Àúµµ ºÎ´ã½º·¯¿îµ¥, °á±¹ ¹ú½á Áß 2°¡ µÇ¾ú½À´Ï´Ù.

¼Ò¾Æ ȯÀÚµéÀº ½Äµµ³ª »óºÎÀ§Àå°ü ħ¹üµµ ÈçÇÕ´Ï´Ù. ¸Å¿ì ½ÉÇÏ´Ù´Â Áõ°ÅÀÔ´Ï´Ù. ÁÁÀº ¾àÀ» »¡¸® »ç¿ëÇØ¾ß µË´Ï´Ù. ƯÈ÷ ½ÉÇÑ ¼Ò¾Æ ȯÀÚµéÀº.


[2022-1-23] »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â°ú ±è¹ÌÁø ±³¼ö´Ô ÆÀ¿¡¼­ gastric oulte obstructionÀ¸·Î ³»¿øÇÑ ¼Ò¾Æ Å©·Ð 2¸í (°¢±â 15»ì, 14»ì) Áõ·Ê¸¦ ¹ßÇ¥Çϼ̽À´Ï´Ù. (Intest Res 2021) InfliximabÀ» ÀÏÂï »ç¿ëÇÑ °ÍÀÌ µµ¿òÀÌ µÇ¾ú´Ù°í ÇÕ´Ï´Ù.

Esophagogastroduodenoscopy at diagnosis (case 1). (A, B) Upper endoscopic findings at referral. Reflux esophagitis at low esophagus, multiple esophageal ulcers, and significant narrowing of pylorus. (C, D) Follow-up upper endoscopic findings after 11 weeks. Apparent pyloric obstruction and multiple ulcerations on antrum. (E, F) Fluoroscopically guided balloon dilation. (G, H) Follow-up upper endoscopic findings after 20 weeks. Remarkable improvement of reflux esophagitis and pyloric obstruction.


[2023-10-8] ±¹Á¦¼Ò¾Æ°úÇÐȸ¿¡¼­ ¹ßÇ¥µÈ »ï¼º¼­¿ïº´¿ø ¼Ò¾Æû¼Ò³â°ú ¼Ò¾ÆÅ©·Ðº´ ÇöȲ


[References]

1) ºÎ¸ð´ÔµéÀÌ °¡Àå °ÆÁ¤ÇÏ´Â ¼Ò¾Æ ¿°Áõ¼º ÀåÁúȯÀÇ Ä¡·á¿¡ ÇÙ½É ´äº¯!

2021-2

2) SMC ¼Ò¾Æû¼Ò³â°ú ±è¹ÌÁø ±³¼ö´Ô ªÀº µ¿¿µ»ó 2021-12

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.